[Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases].

In recent years, immunotherapy has been progressing rapidly in tumor treatment, among which, adoptive immunotherapy of immunologically active cells has also gained increasing attention in the treatment of malignant hematological diseases. Tumor-infiltrating lymphocytes are a heterogeneous class of T-cell-based lymphocytes with high heterogeneity. As an important component of the tumor microenvironment, TILs are crucial in the development of malignant tumors. TILs are a new type of immunoreactive cells discovered after lymphokine-activated killer cells, which can show high specificity and efficacy without the need for large amounts of interleukin-2. Tumor immunotherapy with TILs has shown encouraging results and is valuable in determining patient prognosis. In this paper, we review the composition and characteristics of TILs and their progress in malignant hematologic diseases.

[Research progress of CAR-macrophages in malignant hematological diseases].

This article reviews the development history of chimeric antigen receptor macrophage (CAR-M) therapy, discusses its application in malignant hematologic diseases, introduces related clinical trials, analyzes the advantages and challenges faced by CAR-M therapy in clinical application, and looks forward to its future use in the treatment of malignant hematologic diseases.

Kinetic studies on Korean serum cis-AB enzymes reveal diminished A and B transferase activities.

BACKGROUND: cis-AB enzymes are rare glycosyltransferases that synthesize both blood group A and B antigens. We have identified a large cohort of Korean cis-AB blood donors and studied the N-acetylgalactosaminyltransferase (glycosyltransferase A, GTA) and galactosyltransferase (glycosyltransferase B, GTB) activity of their cis-AB serum enzymes. MATERIALS AND METHODS: The cis-AB01 allele was identified by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) in 60 donors collected at the Gwangju-Chonnam Red Cross Blood Center. Enzyme assays of this cis-AB enzyme were performed on available serum samples from 16 donors with the cis-AB01/O genotype and three with the cis-AB01/A genotype. RESULTS: In cis-AB donors with an O allele, both the GTA and GTB activity of the cis-AB enzyme were markedly reduced compared to normal A and B controls (29% and 27%, respectively). This is consistent with the behaviour predicted from kinetic studies of a recombinant model of the corresponding AAAB enzyme. CONCLUSION: Although variable, cis-AB enzymes feature reduced GTA and GTB activities. SUMMARY: Cis-AB enzymes feature variable but reduced GTA and GTB activities with relatively weaker GTB activity, consistent with the weak agglutination present on forward typing with anti-B.